跳至主要内容
临床试验/CTRI/2024/04/065689
CTRI/2024/04/065689尚未招募Unknown

This is prospective observational study of PegEPO usage in CKD population wherein the drug will be used as part of the routine therapy for management of anemia in CKD population - NI

Apex Kidney Care Pvt. Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • (1.) Greater than 18 years
  • (2.) CKD patients stage IV-V (Non Dialysis) and Maintenance Haemodialysis patients (greater or equal to 3 months), Both ESA naïve and switchover patients from other ESAs.
  • (3.) Patients on rEPO/ DPO with stable dosing for 3 months.
  • (4.) Hb- 7 to 10g/dl.
  • (5.) Tsat %: greater than 20%.
  • (6.) Ferritin greater than 100 mcg/l

排除标准

  • (1.) Any patient who does not fit the inclusion criteria as per physician’s opinion or not fit for PegEPO therapy as per PI.
  • (2.) Patient with a history of hypersensitivity reactions or contraindication to the excipients of Peg EPO.

研究者

发起方
Apex Kidney Care Pvt. Ltd.

相似试验